Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer02:18

Cancer

51.8K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preserving Medical Education in Conflict Zones through Transnational Partnerships: Field Lessons from Gaza and Ukraine.

Disaster medicine and public health preparedness·2026
Same author

Ayushman Arogya Mandir and India's progress toward Universal Health Coverage: A narrative review.

Journal of family medicine and primary care·2026
Same author

Survival comparison analysis between cervical squamous cell carcinoma and adenocarcinoma with a special focus on the HPV status.

Gynecologic oncology·2026
Same author

Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.

Gynecologic oncology·2025
Same author

Impact of molecular and immune signature on endometrial biopsies with atypical hyperplasia with and without concurrent endometroid carcinoma.

Gynecologic oncology reports·2025
Same author

30-hydroxygambogic acid increases the efficacy of cisplatin in an HPV<sup>+</sup> head and neck cancer in vivo model.

BMC cancer·2025

Related Experiment Video

Updated: May 5, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.9K

Breast carcinoma: molecular profiling and updates.

Sudeshna Bandyopadhyay1, Rouba Ali-Fehmi

  • 1Department of Pathology, Wayne State University, 540 E Canfield Street, Detroit, MI 48201, USA.

Clinics in Laboratory Medicine
|November 26, 2013
PubMed
Summary

Molecular subtyping of breast cancer identified distinct estrogen-positive and estrogen-negative subtypes, guiding prognosis and therapy. Histopathology and biomarker evaluation offer similar prognostic insights, while genetic analysis reveals new therapeutic targets.

Keywords:
Breast cancerBreast carcinomaMolecular profilingUpdates

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.1K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

11.7K

Related Experiment Videos

Last Updated: May 5, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.9K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.1K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

11.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Molecular subtyping of breast carcinomas is crucial for distinguishing distinct tumor subtypes.
  • Estrogen receptor status (estrogen-positive vs. estrogen-negative) defines key entities with different prognoses and therapeutic needs.

Purpose of the Study:

  • To highlight the significance of molecular subtyping in breast cancer.
  • To emphasize the prognostic and therapeutic implications of tumor subtypes.
  • To explore the role of genetic alterations in identifying novel therapeutic targets and understanding cancer progression.

Main Methods:

  • Molecular and genetic analyses of breast carcinomas.
  • Histopathologic evaluation.
  • Assessment of predictive biomarkers.

Main Results:

  • Identification of estrogen-positive and estrogen-negative tumor subtypes with distinct clinical behaviors.
  • Prognostic information can be obtained through molecular/genetic analyses, histopathology, and biomarker evaluation.
  • Genetic alterations offer potential for novel therapeutic target discovery.

Conclusions:

  • Molecular subtyping, particularly estrogen receptor status, is vital for breast cancer management.
  • Histopathology and biomarker assessment provide valuable prognostic data.
  • Understanding genetic alterations and progression pathways can improve risk stratification and treatment strategies for breast cancer patients.